Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Anti-IgE injection for allergic asthma and chronic hives. | Anti-IL-5 antibody for severe eosinophilic asthma. |
| Body system | Lungs & Breathing | Lungs & Breathing |
| Drug class | Asthma biologics | Asthma biologics |
| Supply | Prescription only | Prescription only |
| Main uses | Severe allergic asthma, Chronic spontaneous urticaria (hives), Nasal polyps, Food allergy (US) | Severe eosinophilic asthma, Nasal polyps, Eosinophilic granulomatosis with polyangiitis |
| How it works | Blocks the allergy antibody IgE. | Lowers a type of white cell that drives severe asthma. |
| Starts working | Weeks to months | Weeks to months |
| Half-life | About 26 days | About 16–22 days |
| Typical adult dose | 75–600 mg every 2 or 4 weeks, based on body weight and IgE level for asthma; 150–300 mg every 4 weeks for hives. | 100 mg subcutaneously every 4 weeks for asthma. |
| Forms | Subcutaneous injection | Subcutaneous injection |
| Common side effects | Injection site reactions, Headache, Sore throat, Joint pain | Headache, Injection site reactions, Back pain, Tiredness |
| Serious side effects | Anaphylaxis (rare), Parasite infection risk, Heart or stroke events (possible) | Allergic reactions, Shingles, Parasite infections |
| Don't take if | Previous anaphylaxis to omalizumab | Previous severe hypersensitivity to mepolizumab |
| Alcohol | Usually no problem in moderation. No known interaction. | Usually no problem in moderation. No known interaction. |
| Pregnancy | Use with cautionUsed if needed; data do not show harm. | Use with cautionLimited data. |
| Breastfeeding | Generally considered safeAntibodies pass into milk in small amounts. | Generally considered safeAntibodies pass into milk in small amounts. |
| In use since | — | — |
| Brand names | United States: XolairUnited Kingdom: XolairIndia: Xolair, Omalizumab (generic) | United States: NucalaUnited Kingdom: NucalaIndia: Nucala |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H |
| ATC code | R03DX05 | R03DX09 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker